Biykem Bozkurt, MD, PhD, explains why survodutide, a glucagon and GLP-1 dual agonist, needed a cardiovascular safety trial in patients with obesity.
Biykem Bozkurt, MD, PhD
Advertisement
Biykem Bozkurt, MD, PhD, is a professor of medicine and the senior dean of faculty at Baylor College of Medicine.
Articles by Biykem Bozkurt, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Survodutide Meets CV Safety End Point in SYNCHRONIZE-CVOT
2
FDA Approves First Dual-Targeted Therapy for Advanced HNSCC
3
Pharmacy, Claims Data Show High Resmetirom Persistence in MASH
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5